S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
Log in

NASDAQ:PTLA - Portola Pharmaceuticals Stock Price, Forecast & News

$28.25
-0.96 (-3.29 %)
(As of 12/9/2019 04:00 PM ET)
Today's Range
$28.18
Now: $28.25
$29.53
50-Day Range
$26.90
MA: $28.69
$30.62
52-Week Range
$14.81
Now: $28.25
$37.95
Volume923,301 shs
Average Volume1.12 million shs
Market Capitalization$2.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.07
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTLA
CUSIPN/A
Phone650-246-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40.13 million
Book Value$1.36 per share

Profitability

Net Income$-350,220,000.00
Net Margins-275.13%

Miscellaneous

Employees324
Market Cap$2.20 billion
Next Earnings Date3/6/2020 (Estimated)
OptionableOptionable

Receive PTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter.


Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals Inc (NASDAQ:PTLA) announced its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.68) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.82) by $0.14. The biopharmaceutical company had revenue of $36.80 million for the quarter, compared to analysts' expectations of $34.64 million. Portola Pharmaceuticals had a negative return on equity of 282.04% and a negative net margin of 275.13%. The firm's revenue was up 159.2% on a year-over-year basis. During the same period in the prior year, the business posted ($1.08) earnings per share. View Portola Pharmaceuticals' Earnings History.

When is Portola Pharmaceuticals' next earnings date?

Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 6th 2020. View Earnings Estimates for Portola Pharmaceuticals.

What price target have analysts set for PTLA?

8 Wall Street analysts have issued 1 year price objectives for Portola Pharmaceuticals' shares. Their forecasts range from $35.00 to $45.00. On average, they expect Portola Pharmaceuticals' share price to reach $40.00 in the next year. This suggests a possible upside of 41.6% from the stock's current price. View Analyst Price Targets for Portola Pharmaceuticals.

What is the consensus analysts' recommendation for Portola Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portola Pharmaceuticals in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Portola Pharmaceuticals.

What are Wall Street analysts saying about Portola Pharmaceuticals stock?

Here are some recent quotes from research analysts about Portola Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (10/9/2019)
  • 2. William Blair analysts commented, "We are encouraged by the continued growth of Andexxa, particularly with 74% of sales in the quarter coming from hospitals reordering Andexxa. In addition, management commentary continues to be positive, highlighting the increased utilization trends with current accounts, recent increase in CMS NT AP reimbursement level (to 65% from 50%), access to the Veterans Administration health system, and first sales in Europe. We believe there is continued long- term momentum for Andexxa beyond the addition of new accounts over the next several quarters, including strong growth of the factor Xa class, label expansion to include urgent surgery and enoxaparin, and continued guidance recommendations including the recent Joint Commission updates." (8/9/2019)
  • 3. Cowen Inc analysts commented, "We look forward to the first in human data using the “Process B” and believe its use of higher cell doses, transduction enhancers, and commercial-grade vectors will promote higher VCN (≥1) resulting in more clinically meaningful outcomes." (5/8/2019)

Has Portola Pharmaceuticals been receiving favorable news coverage?

News stories about PTLA stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Portola Pharmaceuticals earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the near term. View News Stories for Portola Pharmaceuticals.

Who are some of Portola Pharmaceuticals' key competitors?

What other stocks do shareholders of Portola Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Portola Pharmaceuticals investors own include Lexicon Pharmaceuticals (LXRX), Novavax (NVAX), Editas Medicine (EDIT), Iovance Biotherapeutics (IOVA), Exelixis (EXEL), Amarin (AMRN), Geron (GERN), NVIDIA (NVDA), Alibaba Group (BABA) and Inovio Pharmaceuticals (INO).

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the folowing people:
  • Ms. Mardi C. Dier, Exec. VP, Chief Bus. Officer & CFO (Age 55)
  • Dr. John T. Curnutte, Exec. VP and Head of R&D (Age 67)
  • Mr. J. Scott Garland M.B.A., MBA, Pres & CEO (Age 50)
  • Cara Miller, VP of Investor Relations and Corp. Communications
  • Mr. John B. Moriarty Jr., Exec. VP, Gen. Counsel & Sec. (Age 51)

Who are Portola Pharmaceuticals' major shareholders?

Portola Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (4.10%), Tamarack Advisers LP (1.46%), Emerald Advisers LLC (0.73%), Peregrine Capital Management LLC (0.70%), Emerald Mutual Fund Advisers Trust (0.69%) and Tocqueville Asset Management L.P. (0.58%). Company insiders that own Portola Pharmaceuticals stock include Charles J Homcy, Henry Ward Wolff, Hollings Renton, Jeffrey W Bird, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.

Which institutional investors are selling Portola Pharmaceuticals stock?

PTLA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, First Trust Advisors LP, Sector Gamma AS, Tocqueville Asset Management L.P., Emerald Advisers LLC, Creative Planning, Fisher Asset Management LLC and grace capital. Company insiders that have sold Portola Pharmaceuticals company stock in the last year include Charles J Homcy, Hollings Renton and Mardi Dier. View Insider Buying and Selling for Portola Pharmaceuticals.

Which institutional investors are buying Portola Pharmaceuticals stock?

PTLA stock was bought by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, Chicago Equity Partners LLC, Pictet Asset Management Ltd., Millennium Management LLC, State of New Jersey Common Pension Fund D, GW&K Investment Management LLC, California Public Employees Retirement System and Empire Life Investments Inc.. View Insider Buying and Selling for Portola Pharmaceuticals.

How do I buy shares of Portola Pharmaceuticals?

Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of PTLA stock can currently be purchased for approximately $28.25.

How big of a company is Portola Pharmaceuticals?

Portola Pharmaceuticals has a market capitalization of $2.20 billion and generates $40.13 million in revenue each year. The biopharmaceutical company earns $-350,220,000.00 in net income (profit) each year or ($5.01) on an earnings per share basis. Portola Pharmaceuticals employs 324 workers across the globe.View Additional Information About Portola Pharmaceuticals.

What is Portola Pharmaceuticals' official website?

The official website for Portola Pharmaceuticals is http://www.portola.com/.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]


MarketBeat Community Rating for Portola Pharmaceuticals (NASDAQ PTLA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  485 (Vote Outperform)
Underperform Votes:  329 (Vote Underperform)
Total Votes:  814
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe PTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel